Drug Approval | November 24, 2021
U.S. FDA approves first treatment for drug-resistant post-transplant infection
The approval is for Cytomegalovirus, a type of Herpes virus
The approval is for Cytomegalovirus, a type of Herpes virus
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
State-of-the-art R&D facility designed to foster collaboration across world-class science ecosystem
CStone granted the exclusive rights to Hengrui for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth
Subscribe To Our Newsletter & Stay Updated
